Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.
Mbalaviele G, Pauley AM, Shaffer AF, Zweifel BS, Mathialagan S, Mnich SJ, Nemirovskiy OV, Carter J, Gierse JK, Wang JL, Vazquez ML, Moore WM, Masferrer JL. Mbalaviele G, et al. Among authors: mathialagan s. Biochem Pharmacol. 2010 May 15;79(10):1445-54. doi: 10.1016/j.bcp.2010.01.003. Epub 2010 Jan 11. Biochem Pharmacol. 2010. PMID: 20067770
A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models.
Mbalaviele G, Sommers CD, Bonar SL, Mathialagan S, Schindler JF, Guzova JA, Shaffer AF, Melton MA, Christine LJ, Tripp CS, Chiang PC, Thompson DC, Hu Y, Kishore N. Mbalaviele G, et al. Among authors: mathialagan s. J Pharmacol Exp Ther. 2009 Apr;329(1):14-25. doi: 10.1124/jpet.108.143800. Epub 2009 Jan 23. J Pharmacol Exp Ther. 2009. PMID: 19168710
Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation.
Sommers CD, Thompson JM, Guzova JA, Bonar SL, Rader RK, Mathialagan S, Venkatraman N, Holway VW, Kahn LE, Hu G, Garner DS, Huang HC, Chiang PC, Schindler JF, Hu Y, Meyer DM, Kishore NN. Sommers CD, et al. Among authors: mathialagan s. J Pharmacol Exp Ther. 2009 Aug;330(2):377-88. doi: 10.1124/jpet.108.147538. Epub 2009 May 28. J Pharmacol Exp Ther. 2009. PMID: 19478133
Novel insights into the cellular mechanisms of the anti-inflammatory effects of NF-kappaB essential modulator binding domain peptides.
Baima ET, Guzova JA, Mathialagan S, Nagiec EE, Hardy MM, Song LR, Bonar SL, Weinberg RA, Selness SR, Woodard SS, Chrencik J, Hood WF, Schindler JF, Kishore N, Mbalaviele G. Baima ET, et al. Among authors: mathialagan s. J Biol Chem. 2010 Apr 30;285(18):13498-506. doi: 10.1074/jbc.M109.099895. Epub 2010 Feb 18. J Biol Chem. 2010. PMID: 20167598 Free PMC article.
Inhibition of IKK-2 by 2-[(aminocarbonyl)amino]-5-acetylenyl-3-thiophenecarboxamides.
Bonafoux D, Bonar S, Christine L, Clare M, Donnelly A, Guzova J, Kishore N, Lennon P, Libby A, Mathialagan S, McGhee W, Rouw S, Sommers C, Tollefson M, Tripp C, Weier R, Wolfson S, Min Y. Bonafoux D, et al. Among authors: mathialagan s. Bioorg Med Chem Lett. 2005 Jun 2;15(11):2870-5. doi: 10.1016/j.bmcl.2005.03.090. Bioorg Med Chem Lett. 2005. PMID: 15911271
Aminopyridinecarboxamide-based inhibitors: Structure-activity relationship.
Bonafoux DF, Bonar SL, Clare M, Donnelly AM, Glaenzer JL, Guzova JA, Huang H, Kishore NN, Koszyk FJ, Lennon PJ, Libby A, Mathialagan S, Oburn DS, Rouw SA, Sommers CD, Tripp CS, Vanella LJ, Weier R, Wolfson SG, Huang HC. Bonafoux DF, et al. Among authors: mathialagan s. Bioorg Med Chem. 2010 Jan 1;18(1):403-14. doi: 10.1016/j.bmc.2009.10.040. Epub 2009 Oct 27. Bioorg Med Chem. 2010. PMID: 19914076
49 results